HER2-Positive Gastrointestinal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss …
Gastroesophageal Cancers — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Prof Eric Van Cutsem, moderated by Dr Janjigian, including the following topics:
Introduction (0:00)
HER2-Targeted Approaches in Advanced Gastroesophageal Cancers — Prof Van Cutsem (2:08)
Targeting CLDN18.2 in Advanced Gas…
Gastroesophageal Cancers — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Prof Eric Van Cutsem, moderated by Dr Janjigian, including the following topics:
Introduction (0:00)
HER2-Targeted Approaches in Advanced Gastroesophageal Cancers — Prof Van Cutsem (2:08)
Targeting CLDN18.2 in Advanced Gastroe…
Gastroesophageal Cancers — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Prof Eric Van Cutsem, moderated by Dr Janjigian, including the following topics:
Introduction (0:00)
HER2-Targeted Approaches in Advanced Gastroesophageal Cancers — Prof Van Cutsem (2:08)
Targeting CLDN18.2 in Advanced Gastroe…
Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers
Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers
Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers
Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers
Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers
Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers
Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers
Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers
Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers
Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers
Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers
Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers
محرك بحث البودكاست
يمكنك استخدام موقعنا الإلكتروني للبحث في ملفات podcast3,825,344وحلقات195,854,442حسب الأشخاص أو الأماكن أو المواضيع.
الاستثمار في المعرفة يحقق أفضل عائد، ولذلك أستمع إلى البودكاست.
‐ Benjamin "Llamacorn" Franklin
تعديل
شكراً على مساعدتنا في الحفاظ على قاعدة بيانات البودكاست مُحدَّثة.
